爱美客神话不再近10年业绩首双降 14亿收购“童颜针”尚未见成效

Core Viewpoint - Aimeike, known as "the Moutai for women," is experiencing a significant decline in its business performance, with both revenue and net profit dropping sharply in recent quarters [1][5][10]. Financial Performance - In the first three quarters of 2025, Aimeike reported revenue exceeding 1.86 billion yuan, a year-on-year decrease of over 21%, and a net profit of nearly 1.1 billion yuan, down over 30% [1][5]. - This marks the first time in nearly a decade that Aimeike has experienced a decline in both revenue and net profit over three quarters [2][8]. - The company has seen a continuous decline in performance for four consecutive quarters, with no signs of recovery [2][8]. Product Performance - Aimeike's core products have lost market share, with revenue from its two main products declining in the first half of 2025 [3][11]. - The acquisition of the "童颜针" (Youth Needle) for nearly 1.4 billion yuan has not yet shown positive results in the company's financials [3][12]. - The revenue contribution from Aimeike's main products, including "嗨体" and "濡白天使," has decreased significantly, dropping from 98.57% in 2023 to 95.24% in the first half of 2025 [11][12]. Market Competition - The medical aesthetics industry is facing intensified competition, leading to squeezed profit margins for Aimeike [10][11]. - The market is shifting from expansion to value reconstruction, with a notable increase in competition from new entrants and evolving consumer demands [10][11]. - Aimeike's main products, which include gel and solution injection products, are facing challenges from competitors like 华熙生物 and 圣博玛, which have introduced similar products to the market [11][12]. Historical Context - Aimeike's revenue and net profit had been growing rapidly from 2016 to 2023, with revenue increasing from 141 million yuan to 2.87 billion yuan and net profit from 53 million yuan to 1.86 billion yuan during the same period [5][6]. - The company experienced a slowdown in growth starting in 2024, with revenue and net profit growth rates falling to single digits for the first time since 2016 [6][10].